(CercleFinance.com) – Oddo BHF which goes from ‘neutral’ to ‘outperforming’ on bioMérieux and brings it into its ‘european midcap list’, with a price target maintained at 105 euros, given the share’s recent decline that the visibility seems good to him.
‘bioMérieux should benefit from several growth opportunities in the short and medium term’, believes the analyst, who cites in particular its new lowplex diagnostic systems, SpotFire, launched last March in the United States.
Once the hypothesis of a slowdown in sales of respiratory panels has been adopted, Oddo BHF believes that consolidated sales should grow by +4% to +6%, at constant currencies and scope (i.e. 8-10% excluding respiratory panels linked to Covid) in 2023.
“The stock is trading at 16x 12-month EBIT, below its 10-year average of 19x, despite an industry position that has never looked so favourable,” he said. highlighting, among other things, higher margins than before the Covid.
Copyright © 2023 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
